ClinEdge Announced as a Finalist in Excellence in Rare Disease Drug Development

QUINCY, MA – February 27, 2019 – ClinEdge has been named a finalist in the Excellence in Rare Disease Drug Development category in the CARE Awards, which recognizes companies that dedicate themselves to rare disease work across the global clinical research enterprise.

The 2019 winners will be announced at a ceremony on Thursday, May 2, 2019 at the Hyatt Regency in Boston, MA, where distinguished leaders in the biopharmaceutical, CRO, and diagnostic industries gather from all corners of the globe.

The ClinEdge Rare Disease program utilizes defined methods to compassionately engage, partner, and empower rare disease patients and their families. Our global strategies improve the clinical trial process by using the voice of the patient to build and support clinical trial programs, using their own journey and story to increase patient engagement and retention. To be nominated in a category that recognizes excellence in rare disease speaks to the innovation and heart that supports the program’s mission.

The CARE Awards 2019 features 11 categories, which showcase significant accomplishments and highlight innovation across the industry – from rare disease drug development and patient-centricity in trials and research, to product and technological development, clinical results and collaborative efforts between individuals, departments, or companies. Entries are judged independently by a panel of experts from all core sectors of the clinical R&D industry.

“It is truly an honor to be nominated for a CARE Award in 2019,” says ClinEdge President, Christian Burns. “Advancing the care, accessibility, and awareness of clinical trials for rare disease communities has been one of our key company missions since inception. It is humbling to see our rare disease program and its affiliated teams be recognized for their outstanding achievements, and to know that recognition stems from the role we have played in making a positive impact on rare disease research.”

You can view the full list of finalists here:


About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit


About ClinX

ClinX, the parent company of ClinEdgeBTC Network, and GuideStar Research, is a global service solutions provider for research sites, patients, and healthcare organizations involved in managing, conducting, and participating in clinical research. The strength of our unique companies offers a focused vision in building platforms and ecosystems that drive innovation for our clientele and patients.

ClinEdge combines patient recruitment and business development services under one umbrella as a means to empower patients and stakeholders to advance clinical trials as a healthcare option. Our Rare Disease program specifically addresses the unique needs of rare disease patients, and emphasizes the importance of collaborating with patients for ideal clinical outcomes.